DOCSLIB.ORG

The-Engine-Report.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The-Engine-Report.Pdf 04 Introduction KATIE RAE, CEO & Managing Partner 06 08 Our Mission United Nations Sustainable Development Goals 06 What is Tough Tech? 08 Mapping Portfolio Companies across 07 Our Investment Areas UN SDGs 10 Mapping The Engine Initiatives across UN SDGs 12 66 The Engine Initiatives Portfolio Impact 14 Fostering 68 Climate Change Entrepreneurship 98 Human Health within Science & 122 Advanced Systems & Technology Infrastructure 38 Regional Development Encouraging 50 Commercialization of Tough Tech “ Core to our mission is helping incredible founders, ideas, and companies scale. To create lasting impact for the world, we must reach everyone.” The Engine was spun out of MIT the entrepreneurial community fabrication, and of!ce space for 100 government contract to develop that has taken a tragic human toll in 2016, with the purpose of working across Tough Tech; scaling Tough Tech companies. And we and deploy its network of shoebox- and fundamentally altered the way supporting startups poised to create the diversity of backgrounds, continue to convene thousands of sized satellites to help us better we work and live. The pandemic has a material positive impact on society viewpoints, and approaches to people across the growing Tough understand and protect our world. only served to sharpen our collective and the environment. solving our biggest challenges; Tech community during our annual sense of urgency to discover scaling the jobs added to our region Tough Tech Summit, industry- We’re excited to apply the UN and commercialize Tough Tech We had a bold vision for the impact and the infrastructure that those speci!c Provocations, and other Sustainable Development Goals companies. This report puts the Tough Tech could unlock for the working on the toughest problems gatherings. to our portfolio of Tough Tech scope and scale of Tough Tech into world, but we could never have have access to; and scaling the companies. Inside, you’ll !nd an perspective and serves as a reminder predicted how these years would bene!ts to our community. To I’m both humbled and thrilled outline and analysis of how these of why we must continue to create play out. The past two years in create lasting impact for the world, by the progress of the Tough companies, as well as The Engine the frameworks to support those Katie Rae, particular, which this report will we must reach everyone. Tech companies in our portfolio. itself, !t into the established UN solving massive problems, through CEO & Managing Partner aim to detail, have shown us just Commonwealth Fusion Systems framework. the convergence of science and how widespread and systematic the That is what the past two years have published peer reviewed papers technology. We will continue on our challenges we face are, and why the been about. showing that their approach to The two years since our last report journey to do just that — we hope time to tackle them is now. limitless, net-energy fusion power is have been de!ned by a pandemic that you can join us. We recently launched a program likely to succeed. Biobot Analytics, We do this in a few key ways that called Blueprint, which increases E25Bio, C2Sense, and Vaxess leverage our proximity to the world the pipeline of academic Technologies are each working renowned research institutions researchers and post doctorates towards commercial diagnostic in our backyard: promoting who are ready to take the leap into and therapeutic solutions for “ The pandemic has only served to entrepreneurship within science entrepreneurship. We put forth COVID-19 and other conditions. and technology, commercializing policy recommendations for the Mori showed that its natural coating sharpen our collective sense of urgency Tough Tech, and fostering regional new administration to ensure we can extend the shelf life of fresh to discover and commercialize Tough economic development. are unlocking more innovation fruits, vegetables, and protein by Core to each of those tenets is that will bene!t the world. Our 25%-100%, drastically reducing Tech companies.” helping incredible founders, ideas, 155,000 sq/ft expansion project is food waste and the need for single and companies scale. Scaling well underway and slated to open use packaging. And Analytical the access to opportunities and in late 2022 with laboratories, Space recently received a signi!cant 4 THE ENGINE REPORT !"#$ & !"!" INTRODUCTION 5 Our Investment Areas We look for impact across three general areas that will help the world OUR responsibly adapt to the growth and demands of tomorrow: MISSION Launched by MIT, The Engine that will accelerate progress toward bridges the gap between a healthier population, a more discovery and commercialization accessible and adaptive society, and by empowering disruptive a more resilient world. The Engine CLIMATE CHANGE HUMAN HEALTH ADVANCED SYSTEMS & INFRASTRUCTURE technologies with the capital, rewards con!dence and science with Mitigating, adapting to, Enabling a healthier Adapting and evolving knowledge, network connections, capital and access. and ultimately reversing global population through critical industrial and the specialized equipment and the universal crisis of the advancement of biotech systems that provide the labs they need to thrive. We bridge the gap between climate change, with new and life sciences, by backbone of advanced discovery and commercialization materials and processes developing foundational manufacturing and supply Tough Tech companies have by funding and opening access for to adjust energy sources, technologies to improve chains, the built historically been underserved ambitious Tough Tech founders, reduce carbon emissions, health diagnosis and environment, and space. and underfunded, leaving many making possible the future they and redefine energy treatment and application breakthrough inventions stuck want to see in the world. Our storage. of science-driven inside the lab. This is why we focus community makes impossible processes to ensure food exclusively on founders pioneering progress, achievable and the dif!cult security. technology with the genuine ability challenges, solvable. to transform the planet. Together, we identify and champion Everything we do is in the service of the advanced scienti!c foundation our founders and their work. required to connect, support, power, We focus on supporting the and protect tomorrow’s society and A Relationship founders building technologies environment. of Continued Support Tough Tech is transformative technology that We work closely with founders and + Investment and access to the right capital assets executives to help them scale and + Access to flexible infrastructure solves the world’s most important challenges grow their companies to accelerate + Ongoing connection to the right stakeholders across the path to market. capital, government and strategics through the convergence of breakthrough science, + Support on scaling the organization and finding the engineering, and leadership. right talent + Amplifying their stories and positioning them as leaders in their respective industries 6 THE ENGINE REPORT !"#$ & !"!" OUR MISSION 7 No Poverty Zero Mapping The Engine’s Portfolio across Hunger 01 the United Nations Sustainable Development Goals 02 Good Health & Well-being 03 Quality Education 04 ACHIEVING A BETTER Gender Equalilty AND MORE SUSTAINABLE 05 Clean Water & Sanitation FUTURE FOR ALL 06 The UN Sustainable Development Goals recognize that achieving a better and more A!ordable & Clean Energy sustainable future for all requires an integrated approach to solving a diverse set of issues 07 together. The Engine’s portfolio mirrors this approach and re"ects a broad set of impact areas as a whole. We have mapped the portfolio against these UN SDGs to show how many challenges our Decent Work & 08 Economic Growth companies are working to tackle. For example, companies with a core focus on human health can still have an impact on climate change. This illustrates the ripple effects that will be created as this group continues to hit their impact milestones. That progress will be detailed in the portfolio section of this report. 09 Industry, Innovation, & Infrastructure Boston Metal 10 CLIMATE CHANGE Cambridge Electronics Reduced Inequalities Commonwealth Fusion Systems Form Energy Lilac Solutions Quaise Syzygy Plasmonics Via Separations 11 Biobot Analytics Sustainable Cities HUMAN HEALTH Cellino & Communities E25Bio Kytopen Lucy Therapeutics Mori 12 Seaspire Skincare Responsible Consumption & Production Suono Bio Vaxess Technologies Analytical Space ADVANCED SYSTEMS & C2Sense 13 Celestial.ai INFRASTRUCTURE HyperLight Climate Action ISEE Radix Labs 14 RISE Robotics Sync Computing Life below Water The Routing Company 15 WoHo Zapata Computing 16 Life on Land 17 Peace, Partnerships Justice, & Strong for the Goals Institutions 8 THE ENGINE REPORT !"#$ & !"!" UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS 9 No Zero Poverty Hunger Mapping The Engine's Mission Driven Initiatives Across the United Nations 01 Good Health & Well-being 02 Sustainable Development Goals 03 Quality Education 04 Gender Equalilty THE ENGINE’S 05 INITIATIVES Clean Water & Sanitation 06 The United Nations Sustainable Development Goals (UN SDGs) were established in 2015 as “a shared blueprint for peace and prosperity for people and the planet, now and into the future.” They have since been adopted by all UN Member States. A!ordable & Clean Energy 07 Throughout the life of our portfolio companies, we work to amplify their mission and help them scale, so
Load more

Recommended publications
  • Annual Report
    Fiscal Year 2015 Annual Report To: Governor Charlie Baker Secretary of Administration and Finance Kristen Lepore Secretary of Housing & Economic Development Jay Ash Senate President Stan Rosenberg Speaker of the House Robert DeLeo State Comptroller Thomas G. Shack III Clerk of the Senate William Welch Clerk of the House of Representatives Steven James By forward: House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies Date: September 30, 2015 Re: FY 2015 Annual Report of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization’s operations and accomplishments during Fiscal Year (FY) 2015. For the past seven years, the MLSC has led the state’s life sciences initiative – a $1 billion initiative designed to strengthen the state’s economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC’s goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business. The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC’s strategy has been based on the belief that the best role for the state is to invest in Massachusetts’ innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five “enablers” that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.
    [Show full text]
  • View Annual Report
    GENOCEA BIOSCIENCES, INC. FORM 10-K (Annual Report) Filed 02/27/15 for the Period Ending 12/31/14 Address 100 ACORN PARK DRIVE CAMBRIDGE, MA 02140 Telephone 617-876-8191 CIK 0001457612 Symbol GNCA SIC Code 2836 - Biological Products, Except Diagnostic Substances Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36289 Genocea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 51 -0596811 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 100 Acorn Park Drive Cambridge, Massachusetts 02140 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (617) 876-8191 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Title of each class registered Common Stock, $0.001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Annual Report
    HUMAN CAPITAL FISCAL YEAR 2019 ANNUAL REPORT INNOVATION CAPITAL GROWTH CAPITAL INTELLECTUAL CAPITAL The capital of scientific revolution. Fiscal Year 2019 Annual Report • Massachusetts Life Sciences Center • i BOARD OF DIRECTORS TABLE OF CONTENTS A LETTER FROM THE INTERIM PRESIDENT & CEO Michael J. Heffernan Co-Chair; Secretary, Executive Office for Administration & Finance A Letter from the President & CEO ...........................................................................................1 Mike Kennealy Co-Chair; Secretary, Executive Office Vision & Strategy: The Capital of Scientific Revolution ......................................................2 The Patients Are Waiting of Housing & Economic Development Fiscal Year 2019 Highlights and The Bottom Line ..............................................................3 Gary P. Kearney, MD Around the globe, billions of patients and their loved ones await advances in health President, Longwood Urological Associates Human Capital care that will produce the products, devices, and therapies to alleviate suffering, Marty Meehan Internship Challenge: Enhancing Career Exploration improve treatment, and save lives. Much of that attention falls on Massachusetts, as President, University of Massachusetts and Expanding the Talent Pipeline ............................................................................................4 the world looks to our ecosystem to deliver the breakthroughs that further unlock our Peter Parker understanding of human physiology, harness the power of data science,
    [Show full text]
  • Science-USA (Boston+), November 2012
    Schweizerische Eidgenossenschaft Confédération suisse Confederazione Svizzera Confederaziun svizra Science-USA (Boston+), November 2012 Table of Contents 1. Policy ........................................................................................................................................................................................ 1 2. Education .................................................................................................................................................................................. 2 3. Life Science .............................................................................................................................................................................. 3 4. Nano / Micro Technology / Material Science ............................................................................................................................. 4 5. Information & Communications Technology ............................................................................................................................. 6 6. Energy / Environment ............................................................................................................................................................... 6 7. Engineering / Robotics / Space ................................................................................................................................................. 8 8. Physics / Chemistry / Math ......................................................................................................................................................
    [Show full text]
  • LIVIO VALENTI CV 2011-Present VAXESS TECHNOLOGIES, INC
    LIVIO VALENTI CV Livio Valenti is the co-founder of Vaxess Technologies and Giorgio Ruffolo Research Fellow in the Sustainability Science Program at Harvard Kennedy School of Government and the Harvard Global Health Institute. He received a Master in Public Policy from Harvard’s Kennedy School of Government in 2013, where he was the recipient of the Empedocle Maffia Fellowship provided by the Italian Government to one outstanding individual to attend Harvard. While a student at Harvard, he co-founded Vaxess Technologies, an innovative life sciences company that aims to create vaccines that do not need refrigeration. Vaxess has raised $4.75m in venture capital, angel investors, and various public institutions, including the Massachusetts Life Science Center (MLSC). Harvard Business School (HBS) published a case on Vaxess in 2014. Livio was named by Forbes one of the 30 under 30 individuals likely to change the world for his commitment in improving global health and one of the 10 under 40 (PrimiDieci-Under40 2014) most distinguished individuals with Italian origins or Italian nationality currently in the USA by the Italian-American Chamber of Commerce and the Italian Ministry of Foreign Affairs. His academic research at Harvard focuses on the space at the intersection between Government and Business. Livio is researching the potential to sustainably commercialize innovative technologies to improve global health. He is contributing to collaborative work with the Initiative on Innovation and Access to Technologies for Sustainable Development led by William Clark. Professional experience Prior to studying at Harvard, Livio worked for the United Nations in several developing countries. His work included advising government clients and international financing institutions in the identification, appraisal and financing of large investment projects.
    [Show full text]
  • Genocea Biosciences, Inc. (Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Genocea Biosciences, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☒ No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the (3) filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee o was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 1 Genocea Biosciences, Inc.
    [Show full text]
  • RENT a BENCH Biotech Incubators Such As Labcentral Are Lowering Barriers to Entrepreneurship by Trisha Gura, in Cambridge, Massachusetts
    NEWS | FEATURES | ENTREPRENEURSHIP GOT A STARTUP? RENT A BENCH Biotech incubators such as LabCentral are lowering barriers to entrepreneurship By Trisha Gura, in Cambridge, Massachusetts ith its cookie-cutter windows and square-meter facility, now owned by the boxy brick exterior, the build- Massachusetts Institute of Technology ing here on Main Street could be (MIT) and leased to LabCentral, functions just another former 19th century as a life science “incubator” that helps bud- W warehouse or factory. It’s no sur- ding biotech firms combat the soaring costs prise to learn that passenger rail- of lab space and equipment in the red-hot road cars were once built in its spacious Boston-Cambridge region. Any scientist on June 11, 2015 interior. Yet the Cambridge landmark has with an idea and ambition can rent a bench a history not just of production, but also and an office, sharing space, services, and of innovation. In 1876, it housed the office high-cost tools with others pursuing their of Thomas Watson, assistant to Alexander own entrepreneurial dreams. “It is very ex- Graham Bell, when the pair made the first citing because we are there at the nascent two-way long-distance phone call, to Bos- moment of many really, really cool com- ton. In the 20th century, it was home to Po- panies,” says molecular biologist Johannes laroid and the lab of Edwin Land when he Fruehauf, a LabCentral founder. invented the instant camera. It’s also the nascent moment for facili- www.sciencemag.org Today, a nonprofit organization called ties like LabCentral.
    [Show full text]
  • Class of 2013 Employment Overview 76
    HARVARD KENNEDY SCHOOL 617-495-1161 [email protected] www.hks.harvard.edu/career CAREER ADVANCEMENT t t t EMPLOYMENT OVERVIEW Class of 2013 HARVARD KENNEDY SCHOOL t CLASS OF 2013 EMPLOYMENT OVERVIEW This overview reflects the diverse employment choices of Harvard Kennedy School (hks) class of The following report on the class of 2013 May graduates immediately post-graduation. 2013 is based on data collected from The Kennedy School degrees continue to show May through October 2013. The hks resilience in an uncertain economy, with our Office of Career Advancement (oca) employed a variety of data collection graduates settling around the globe and across techniques including an exit survey sectors and industries. We invite you to read taken at graduation, a follow-up survey about how our graduates have chosen to serve in September, and individual email inquiries. Overall response rate was 91 the public good through their professional work. percent; of those, 90 percent reported employment or plans to continue in an educational program as of October. OVERVIEW OF GRADUATING 2013 CLASS from 76 539 students countries 242 international MPA/ID MPA2 62 82 12 43 Concurrent/ Concurrent/ Joint Degree Joint Degree MC/MPA MPP 202 193 32 Concurrent/ Joint Degree 87 Concurrent/Joint Degree Students MBA: 69 / Law: 11 / MD: 5 / Divinity: 1 / Design: 1 HARVARD KENNEDY SCHOOL 617-495-1161 [email protected] www.hks.harvard.edu/career CAREER ADVANCEMENT t t t EMPLOYMENT OVERVIEW Class of 2013 HIGHLIGHTS GRADUATES t Eight graduates were selected as t Nonprofit/ngo employment is down IN 2013 finalists in the U.S.
    [Show full text]
  • Fiscal Year 2015 Annual Report
    Fiscal Year 2015 Annual Report To: Governor Charlie Baker Secretary of Administration and Finance Kristen Lepore Secretary of Housing & Economic Development Jay Ash Senate President Stan Rosenberg Speaker of the House Robert DeLeo State Comptroller Thomas G. Shack III Clerk of the Senate William Welch Clerk of the House of Representatives Steven James By forward: House and Senate Committees on Ways and Means and the Joint Committee on Economic Development and Emerging Technologies Date: September 30, 2015 Re: FY 2015 Annual Report of the Massachusetts Life Sciences Center The Massachusetts Life Sciences Center (MLSC) respectfully submits this Annual Report detailing the organization’s operations and accomplishments during Fiscal Year (FY) 2015. For the past seven years, the MLSC has led the state’s life sciences initiative – a $1 billion initiative designed to strengthen the state’s economy by accelerating the growth of our life sciences sectors in Massachusetts. The MLSC’s goal has been to make Massachusetts the strongest life sciences ecosystem in the world and the best place in the world for life sciences companies to do business. The MLSC collaborates with the private sector to accelerate the pace of innovation and economic development in all regions of Massachusetts. The MLSC’s strategy has been based on the belief that the best role for the state is to invest in Massachusetts’ innovation capacity – the ability to produce and commercialize a flow of innovative life sciences technologies over the long term. Since 2008, the MLSC has invested aggressively in five “enablers” that build innovation capacity: translational research, entrepreneurship, workforce development, infrastructure and collaboration.
    [Show full text]
  • What's Inside
    Newsletter A publication of the Controlled Release Society Volume 34 • Number 2 • 2017 What’s Inside Formulation and Delivery of Mono-N-Oxide Vinblastine Liposomal Formulation for Targeting Non-Small Cell Lung Cancer with Hypoxic Environments In Vitro and In Vivo Evaluation of Controlled Payload Release Using Acoustically Responsive Scaffolds CRS Annual Meeting DDTR Update Science. People. Products. Connect and collaborate with delivery science and technology leaders from academia and industry, under one roof at #CRSboston Join us in Boston, Massachusetts, U.S.A. from July 16–19 for the 2017 Controlled Release Society Annual Meeting & Exposition. Registration is now open! Visit controlledreleasesociety.org/CRSboston for details. 2 Newsletter Ryan Donnelly Vol. 34 • No. 2 • 2017 Editor > TABLE OF CONTENTS 4 From the Editor 5 2017 Controlled Release Society Annual Meeting & Exposition Steven Giannos 7 Scientifically Speaking Editor Formulation and Delivery of Mono-N-Oxide Vinblastine Liposomal Formulation for Targeting Non-Small Cell Lung Cancer with Hypoxic Environments 10 Scientifically Speaking In Vitro and In Vivo Evaluation of Controlled Payload Release Using Acoustically Responsive Scaffolds 13 DDTR Update Drug Delivery and Translational Research Update Medha Joshi Editor 14 People in the News 15 Companies in the News Cover image: Malignant effusion: Pleural fluid cytology of lung (pulmonary) papillary adenocarcinoma, a type of non small cell carcinoma. Pap stain. David Litman / Shutterstock.com Arlene McDowell Editor Bozena Michniak-Kohn Editor Rod Walker Editor 3 > FROM THE EDITOR Editors Ryan Donnelly Steven Giannos Steven Giannos Medha Joshi University of Texas Medical Branch Arlene McDowell Galveston, TX, U.S.A. Bozena Michniak-Kohn Rod Walker The CRS Newsletter is the official Please Come to Boston newsletter of the Controlled Release Society.
    [Show full text]
  • Resi Program Final High
    redefining eARLY sTAGE iNVESTMENTs RESI 3 Early Stage Life Science Investment Just Hit a Home Run! ONSITE GUIDE September 17, 2014 Fenway Park Boston, MA RESIConference.com #RESI3 LifeScienceNation.com EMC Level FENWAY PARK EMC CLUB 3 LEVEL 3 EMC2 SUITE L2 Exit FIELD VIEW Board Room Exit Exit Stairs/Escalators workshopS TO State st. Bar Area pavilion LEVEL PARTNERING Forum REGISTRATION sTATE sTREET PAVILION Level State Street. PAVILION lEVEL 4 FENWAY PARK pRESS ROOM mEDIA dINING TRACK 2 TRACK 1 Exit 13 1 2 12 1 FIELD VIEW 2 12 3 Exit Exit 11 11 3 4 10 10 4 5 5 6 6 7 7 8 9 9 8 15 25 16 25 16 26 32 17 30 17 26 27 28 29 30 31 18 24 27 28 29 18 Stairs/Escalators 24 19 23 23 22 22 21 21 20 20 19 13 14 14 15 Bar Area PANELS Exhibiting companies TO EMC LEVEL pRESENTING companies contents TABLE OF CONTENTS Welcome from Dennis Ford - - - - - - - 2 RESI Schedule - - - - - - 3 Investor Panels - - - - - - - 5 Early Stage Workshops - - - - - - 25 Partnering Forum - - - - - - - 26 RESI Innovation Challenge - - - - - - - 27 Exhibiting Companies - - - - - - 29 Sponsors - - - - - - - 30 Media Partners - - - - - - - 33 1 welcome to resi Life Science Nation would like to welcome you to the third Redening Early Stage Investments (RESI) conference. We're excited to see you here at our new landmark location, Fenway Park. I hope you are ready to get the most out of a day lled with content, meetings and opportunities for everyone who has a stake in the early-stage life science sector.
    [Show full text]
  • Vaxess' Long Road to Heat-Stable Vaccines
    Case Number 2081.0 Technological Innovation for Global Health: Vaxess’ Long Road to Heat-Stable Vaccines It was only April, but 2015 was shaping up to be a busy one for Livio Valenti. The Harvard Kennedy School graduate was named to Forbes’ prestigious “30 under 30” list of the brightest entrepreneurs in science and healthcare, just as Vaxess Technologies, the biotech start-up he co-founded in 2012, was starting to attract atten- tion. Indeed, the company was awarded a research grant from the U.S. National Science Foundation and the U.S. National Institute of Health to put toward the development of heat-stable vaccines—a major honor and accom- plishment, though the grants themselves were modest. Most vaccines had to be refrigerated (or frozen) to preserve their efficacy. However, keeping vaccines at the appropriate temperature from manufacturer to recipient posed significant costs and logistical challenges, especial- ly in many low- and middle-income countries where the majority of the world’s children lived. Valenti believed Vaxess’ technology could provide a potentially simpler, safer approach to heat-stabilizing vaccines from both a scientific and regulatory standpoint—formulating them to withstand a lack of refrigeration—compared to other preservation techniques. In the vaccine field however, the risks and costs of research and development, and lengthy regulatory approval processes were major challenges to advancing products to market. Furthermore, with the greatest need for heat-stable vaccines in developing countries, market incentives for companies to invest in heat-stabilization research and development (R&D) were weak. Still, the U.S. Food and Drug Administration (FDA) had approved silk fibroin—the key ingredient for Vaxess’ platform to heat-stabilize vaccines—for use in medical devices such as surgical sutures and implantable surgical mesh, giving the Vaxess team confidence that their inno- vation would eventually gain FDA approval.
    [Show full text]